Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Chemotherapy in Resectable Stage I-IIIA NSCLC
NCT03366766Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03366766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366766.